SphimgoTec GmbH在系列C中为关键护理生物标志的全球扩展和商业化筹集了5百万欧元的资金。 SphingoTec GmbH raised €5M in Series C funding for global expansion and commercialization of critical care biomarkers.

诊断公司SphingoTec GmbH在Think.Health Ventures领导的C轮融资中筹集了500万欧元,以加速全球扩张,特别是在美国市场,并推动创新生物标志物的商业化. Diagnostics company SphingoTec GmbH raised €5M in Series C funding led by Think.Health Ventures to accelerate global expansion, particularly in the US market, and drive commercialization of innovative biomarkers for critical care. 该公司开发和销售血液基蛋白质生物标志,如用于体外诊断的PenKid(婴儿功能)和Bio-ADM(内分泌功能)。 The company develops and markets blood-based protein biomarkers like penKid (kidney function) and bio-ADM (endothelial function) for in vitro diagnostics. 供资的目的是改善病人的管理和结果。 The funding aims to improve patient management and outcomes.